視網膜生物製劑市場規模、佔有率和成長分析（按藥物類別、適應症、通路和地區分類）—2026-2033年產業預測

預計到 2024 年，全球視網膜生物製劑市場規模將達到 246.4 億美元，到 2025 年將達到 265.1 億美元，到 2033 年將達到 476.4 億美元，預測期（2026-2033 年）的複合年成長率為 7.6%。

視網膜生物製劑市場正經歷顯著成長，主要受視網膜疾病（尤其是老齡化黃斑部病變、糖尿病視網膜病變和視網膜靜脈阻塞）發病率上升的推動，而人口老化是造成此現象的主要原因。生物技術和基因工程的進步為基因療法和細胞療法等有效治療方法開闢了新的可能性，從而刺激了相關研究和開發。大眾對這些疾病的認知不斷提高，加上諸如預防失明基金會等機構的教育宣傳，提高了人們對早期診斷和治療方案的了解。在新興市場，特別是中國、巴西和印度等國家，醫療基礎設施的改善和VEGF-A拮抗劑療法的日益普及正在推動市場進一步成長。整體而言，視網膜生物製劑市場前景廣闊，成熟市場和發展中市場均對此表示支持。

全球視網膜生物製劑市場促進因素

美國糖尿病視網膜病變發生率的上升正對全球視網膜生物製劑市場產生重大影響。許多患者被診斷出患有此病，面臨更高的視力喪失風險。隨著糖尿病視網膜病變盛行率的持續成長，對有效治療方法的需求也日益增加。預計這一趨勢將推動對視網膜生物製劑的需求，從而顯著擴大市場規模。人們對視覺健康的日益關注以及對創新解決方案的需求，將在未來幾年進一步促進市場成長。

限制全球視網膜生物製劑市場的因素

全球視網膜生物製劑市場面臨嚴峻挑戰，其中最主要的原因是這些藥物價格高昂，發展中國家的患者難以負擔治療費用，這限制了他們獲得治療的機會。此外，生物製藥的研發和商業化過程本身就十分複雜，而嚴格的監管要求更使其雪上加霜，可能阻礙市場擴張。這些障礙不僅限制了病患的用藥，也延緩了創新治療方法的推出，最終影響到經濟和基礎設施資源匱乏地區的病患治療效果。因此，這些因素共同限制了視網膜生物製劑市場的成長。

全球視網膜生物製劑市場趨勢

全球視網膜生物製劑市場正經歷重大變革，其主要驅動力是基因治療方法的進步，包括針對遺傳性視網膜營養不良的基因療法。這些研發成果正在革新治療格局，並提升視網膜生物製劑的療效。這促使創新治療方案的湧現，以滿足視網膜疾病患者尚未滿足的需求。加之生物製藥創新領域投資的不斷增加以及對視網膜病理學認知的不斷深入，這一市場趨勢預示著視網膜疾病患者擁有光明的未來，有望獲得更佳的治療效果和更高的生活品質。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術進步
• 貿易分析
• 客戶和購買標準分析

全球視網膜生物製劑市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• VEGF-A拮抗劑
• TNF-α抑制劑

全球視網膜生物製劑市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 老齡化黃斑部病變
• 糖尿病黃斑部水腫
• 糖尿病視網膜病變
• 葡萄膜炎
• 其他

全球視網膜生物製劑市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 向醫療機構銷售
• 零售藥房
• 郵購藥房
• 零售

全球視網膜生物製劑市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Regeneron Pharmaceuticals Inc.（USA）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Johnson & Johnson（USA）
• Biogen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol-Myers Squibb Company（USA）
• Sanofi Genzyme（France）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch & Lomb Incorporated（USA）
• Adverum Biotechnologies, Inc.（USA）
• MeiraGTx Holdings plc（UK）
• Oxurion NV（Belgium）
• Kodiak Sciences Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Neurotech Pharmaceuticals, Inc.（USA）
• Opthea Limited（Australia）

結論與建議

Global Retinal Biologics Market size was valued at USD 24.64 Billion in 2024 and is poised to grow from USD 26.51 Billion in 2025 to USD 47.64 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The retinal biologics market is witnessing significant growth driven by an increase in retinal diseases, particularly age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, primarily due to an aging population. Advancements in biotechnology and genetic engineering are unlocking new potential for effective treatments, such as gene and cell-based therapies, encouraging a resurgence in research and development. Growing public awareness of these conditions, alongside advocacy from organizations like the Foundation Fighting Blindness, is enhancing recognition for early diagnosis and treatment options. Emerging markets, particularly in countries like China, Brazil, and India, are further boosting growth through improved healthcare infrastructure and increased adoption of VEGF-A antagonist therapies. Overall, the retinal biologics market presents a promising outlook fueled by both established and developing regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Biologics Market Segments Analysis

Global Retinal Biologics Market is segmented by Drug Class, Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into VEGF-A Antagonists and TNF-a Inhibitors. Based on Indication, the market is segmented into Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Uveitis and Others. Based on Distribution Channel, the market is segmented into Institutional Sales, Retail Pharmacies, Mail Order Pharmacies and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Biologics Market

The rising incidence of diabetic retinopathy in the United States is significantly influencing the Global Retinal Biologics market. A substantial number of individuals are diagnosed with this condition, with many at an increased risk of vision impairment. As the prevalence of diabetic retinopathy continues to grow, so does the urgency for effective treatment options. This trend is expected to propel the demand for retinal biologics, leading to substantial market expansion. The increasing awareness of visual health and the need for innovative solutions to address this widespread issue will further contribute to the market's growth trajectory in the forthcoming years.

Restraints in the Global Retinal Biologics Market

The global retinal biologics market faces significant challenges due to the high costs associated with these drugs, limiting access for individuals in developing countries who often struggle to afford such treatments. Additionally, the complex process of developing and commercializing these biologics is compounded by stringent regulatory requirements, which can further impede market expansion. These barriers not only restrict accessibility but also slow down the introduction of innovative therapies, ultimately affecting patient outcomes in regions where financial and infrastructural resources are limited. As a result, these factors collectively pose notable restraints on the growth of the retinal biologics market.

Market Trends of the Global Retinal Biologics Market

The Global Retinal Biologics market is witnessing a significant shift driven by advancements in genetic treatment approaches, particularly in gene therapy for inherited retinal dystrophies. These progressive research developments are revolutionizing the therapeutic landscape, enhancing the efficacy of retinal biologic drugs. As a result, a surge in innovative treatment options is emerging, catering to the unmet needs of patients with retinal disorders. Coupled with increasing investments in biopharmaceutical innovation and a growing understanding of retinal pathology, this market trend is indicative of a brighter future for those affected by retinal diseases, promising improved outcomes and quality of life.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis
• Customer & Buying Criteria Analysis

Global Retinal Biologics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• VEGF-A Antagonists
• TNF-a Inhibitors

Global Retinal Biologics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Biologics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

Global Retinal Biologics Market Size & CAGR (2026-2033)

• North America (Drug Class, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Genzyme (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch & Lomb Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotech Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opthea Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations